{
  "id": "640ddbe9201352f04a000027",
  "type": "factoid",
  "question": "What is the generic name for Imfinzi?",
  "ideal_answer": "Durvalumab (Imfinzi) is used to treat locally advanced or metastatic cancer.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/30917623",
    "http://www.ncbi.nlm.nih.gov/pubmed/32727810",
    "http://www.ncbi.nlm.nih.gov/pubmed/34731446",
    "http://www.ncbi.nlm.nih.gov/pubmed/29571563",
    "http://www.ncbi.nlm.nih.gov/pubmed/28643244"
  ],
  "snippets": [
    {
      "text": "durvalumab (Imfinzi\u2122; AstraZeneca) is a fully human monoclonal antibody that blocks programmed cell death ligand-1 binding to its receptors (PD-1 and CD80),",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28643244",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "durvalumab (IMFINZI\u00ae, Astra-Zeneca",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29571563",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "durvalumab (Imfinzi\u00ae)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30917623",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Intravenous durvalumab (Imfinzi\u2122; AstraZeneca) is a fully human monoclonal antibody that blocks programmed cell death ligand-1 binding to its receptors (PD-1 and CD80), resulting in enhanced T-cell responses against cancer cells.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28643244",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Durvalumab (IMFINZI\u00ae), a fully human monoclonal antibody against programmed cell death-ligand 1 (PD-L1), is approved for use in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34731446",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Since 2011, the FDA-approved antibody drugs ipilimumab (Yervoy\u00ae), nivolumab (Opdivo\u00ae), pembrolizumab (Keytruda\u00ae), cemiplimab (Libtayo\u00ae), atezolizumab (Tecentriq\u00ae), durvalumab (Imfinzi\u00ae), and avelumab (Bavencio\u00ae), which block the immune checkpoint proteins, have brought about a significant breakthrough in the treatment of a wide range of cancers, as they can induce durable therapeutic responses.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30917623",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Nevertheless, new therapies have emerged recently, among which PD1 immune checkpoint inhibitors (ICI), such as nivolumab (OPDIVO\u00ae, Bristol-Myers Squibb) and pembrolizumab (KEYTRUDA\u00ae, Merck & Co), or PD-L1 ICI, such as atezolizumab (TECENTRIQ\u00ae, Genentech), durvalumab (IMFINZI\u00ae, Astra-Zeneca), and avelumab (BAVENCIO\u00ae, EMD Serono).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29571563",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "titumor immunity. This unique mechanism of action in CD103+ DCs may contribute to clinical responses as AZD4635 is being evaluated in clinical trials with IMFINZI (durvalumab, \u03b1PD-L1) in patients with solid malignancies.CONCLUSION: We provide evidence implicating suppression of adaptive and innate immunity by adenosine as a mechanism",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32727810",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Durvalumab"
}